AR110381A2 - Inhibidores biarilo de tirosina cinasa de bruton - Google Patents

Inhibidores biarilo de tirosina cinasa de bruton

Info

Publication number
AR110381A2
AR110381A2 ARP170103535A ARP170103535A AR110381A2 AR 110381 A2 AR110381 A2 AR 110381A2 AR P170103535 A ARP170103535 A AR P170103535A AR P170103535 A ARP170103535 A AR P170103535A AR 110381 A2 AR110381 A2 AR 110381A2
Authority
AR
Argentina
Prior art keywords
biutyl
tirosina
cinasa
bruton
inhibitors
Prior art date
Application number
ARP170103535A
Other languages
English (en)
Original Assignee
Sunesis Pharmaceuticals Inc
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc, Biogen Ma Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of AR110381A2 publication Critical patent/AR110381A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un compuesto, caracterizado por que es de fórmula (1); (2); o (3), o su sal farmacéuticamente aceptable.
ARP170103535A 2013-12-11 2017-12-15 Inhibidores biarilo de tirosina cinasa de bruton AR110381A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
AR110381A2 true AR110381A2 (es) 2019-03-20

Family

ID=52302344

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104620A AR098721A1 (es) 2013-12-11 2014-12-11 Inhibidores de biarilo de tirosina quinasa de bruton
ARP170103535A AR110381A2 (es) 2013-12-11 2017-12-15 Inhibidores biarilo de tirosina cinasa de bruton

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104620A AR098721A1 (es) 2013-12-11 2014-12-11 Inhibidores de biarilo de tirosina quinasa de bruton

Country Status (32)

Country Link
US (4) US9809577B2 (es)
EP (3) EP3080103B9 (es)
JP (4) JP6431914B2 (es)
KR (1) KR102413253B1 (es)
CN (3) CN106459002B (es)
AR (2) AR098721A1 (es)
AU (2) AU2014362231B2 (es)
BR (1) BR112016012860A2 (es)
CA (1) CA2932608C (es)
CL (2) CL2016001435A1 (es)
CY (1) CY1120517T1 (es)
DK (1) DK3080103T3 (es)
EA (2) EA030538B1 (es)
ES (1) ES2678021T3 (es)
HR (1) HRP20181109T1 (es)
HU (1) HUE040346T2 (es)
IL (2) IL246031B (es)
LT (1) LT3080103T (es)
MX (2) MX388978B (es)
MY (1) MY179781A (es)
NZ (1) NZ721217A (es)
PH (1) PH12016501107B1 (es)
PL (1) PL3080103T3 (es)
PT (1) PT3080103T (es)
RS (1) RS57662B1 (es)
SA (1) SA518391170B1 (es)
SG (2) SG11201604595VA (es)
SI (1) SI3080103T1 (es)
SM (1) SMT201800373T1 (es)
TW (3) TWI675833B (es)
WO (1) WO2015089337A1 (es)
ZA (1) ZA201706244B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SG11201604595VA (en) 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2016201271A1 (en) * 2015-06-10 2016-12-15 Biogen Ma Inc. Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
AU2016368257C1 (en) * 2015-12-07 2019-12-05 Suzhou Sinovent Pharmaceuticals Co., Ltd. Five-membered heterocyclic amides wnt pathway inhibitor
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
SG11201708680PA (en) * 2016-03-31 2017-11-29 Lion Tcr Pte Ltd Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
US10710993B2 (en) 2016-06-27 2020-07-14 Hangzhou REX Pharmaceutical Co., LTD. Benzofuran pyrazole amine kinase inhibitor
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
JOP20190233A1 (ar) * 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
DK3737677T3 (da) 2018-01-10 2022-01-10 Allinky Biopharma Tetrahydroisoquinolinforbindelser
MD3740481T3 (ro) 2018-01-19 2025-06-30 Cytokinetics Inc Analogi de dihidrobenzofuran și inden în calitate de inhibitori ai sarcomerului cardiac
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US10899753B2 (en) 2018-05-14 2021-01-26 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
MA53914A (fr) * 2018-10-15 2021-08-25 Biogen Ma Inc Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
US12240838B2 (en) 2019-05-15 2025-03-04 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
US20240327380A1 (en) * 2020-08-07 2024-10-03 Biogen Ma Inc. Btk inhibitors
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
IL309528A (en) * 2021-06-21 2024-02-01 Beigene Switzerland Gmbh (R)-glutrimide CRBN ligands and methods of use
EP4457225A4 (en) * 2021-12-30 2025-09-24 Beigene Switzerland Gmbh DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH AN E3 LIGASE LIGAND AND METHODS OF USE
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
CN120457122A (zh) 2023-01-04 2025-08-08 Ab科学有限公司 微管蛋白聚合抑制剂
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2026012424A1 (zh) * 2024-07-10 2026-01-15 江苏恒瑞医药股份有限公司 一种杂芳基类化合物、其制备方法及其在医药上的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ATE398109T1 (de) * 2000-08-08 2008-07-15 Ortho Mcneil Pharm Inc 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005074643A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
UA109412C2 (uk) * 2005-11-01 2015-08-25 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
KR20090077975A (ko) * 2006-11-01 2009-07-16 크로마 데러퓨릭스 리미티드 Ｉｋｋ-베타 세린-트레오닌 단백질 키나아제 억제제
WO2008116064A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
US8697685B2 (en) * 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
JP5095044B1 (ja) 2011-03-31 2012-12-12 美津濃株式会社 アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ
EP2696683A4 (en) 2011-04-12 2014-08-13 Alzheimer S Inst Of America Inc COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
SG11201604595VA (en) 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
RU2016151390A (ru) * 2014-06-04 2018-07-17 Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний
WO2016057500A1 (en) * 2014-10-06 2016-04-14 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Also Published As

Publication number Publication date
CL2016001435A1 (es) 2017-06-09
CL2017001459A1 (es) 2018-03-23
HRP20181109T1 (hr) 2018-11-02
CN106459002B (zh) 2018-08-21
US20180093973A1 (en) 2018-04-05
JP2016539996A (ja) 2016-12-22
PH12016501107B1 (en) 2021-07-21
JP6526167B2 (ja) 2019-06-05
JP2019163280A (ja) 2019-09-26
IL269569B (en) 2021-03-25
KR20160106072A (ko) 2016-09-09
CY1120517T1 (el) 2019-07-10
KR102413253B1 (ko) 2022-06-27
IL246031B (en) 2019-10-31
MX370103B (es) 2019-12-02
PL3080103T3 (pl) 2018-10-31
IL269569A (en) 2019-11-28
EA037942B1 (ru) 2021-06-10
MX388978B (es) 2025-03-20
US11572356B2 (en) 2023-02-07
SMT201800373T1 (it) 2018-09-13
WO2015089337A1 (en) 2015-06-18
RS57662B1 (sr) 2018-11-30
TW201811772A (zh) 2018-04-01
BR112016012860A2 (pt) 2017-08-08
PT3080103T (pt) 2018-07-23
HUE040346T2 (hu) 2019-03-28
NZ721217A (en) 2021-12-24
US10081619B2 (en) 2018-09-25
ES2678021T3 (es) 2018-08-08
JP2021091733A (ja) 2021-06-17
CA2932608A1 (en) 2015-06-18
DK3080103T3 (en) 2018-07-30
SI3080103T1 (sl) 2018-11-30
US20220332705A1 (en) 2022-10-20
EP3080103B9 (en) 2018-09-19
JP7076022B2 (ja) 2022-05-26
CN108947913A (zh) 2018-12-07
JP2018035201A (ja) 2018-03-08
EP3080103A1 (en) 2016-10-19
EP3357921A3 (en) 2018-09-12
AU2019201997A1 (en) 2019-04-18
CN109096274B (zh) 2022-07-01
SA518391170B1 (ar) 2022-08-25
IL246031A0 (en) 2016-08-02
AU2014362231A1 (en) 2016-07-07
EP3080103B1 (en) 2018-04-18
AU2014362231B2 (en) 2019-04-04
AU2019201997C1 (en) 2021-03-18
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
EP3872075A1 (en) 2021-09-01
US20190218204A1 (en) 2019-07-18
TW202017931A (zh) 2020-05-16
US10759783B2 (en) 2020-09-01
US20160311802A1 (en) 2016-10-27
TW201536765A (zh) 2015-10-01
MY179781A (en) 2020-11-13
ZA201706244B (en) 2019-04-24
US9809577B2 (en) 2017-11-07
LT3080103T (lt) 2018-08-10
EA201792348A1 (ru) 2018-09-28
EP3357921A2 (en) 2018-08-08
CN109096274A (zh) 2018-12-28
TWI675833B (zh) 2019-11-01
MX2016007611A (es) 2016-09-09
EA030538B1 (ru) 2018-08-31
PH12016501107A1 (en) 2016-07-11
JP6431914B2 (ja) 2018-11-28
CA2932608C (en) 2023-02-14
TWI608002B (zh) 2017-12-11
AU2019201997B2 (en) 2020-09-17
CN106459002A (zh) 2017-02-22
AR098721A1 (es) 2016-06-08
SG10201908558WA (en) 2019-10-30
EA201691114A1 (ru) 2016-11-30
MX2019014228A (es) 2020-01-23

Similar Documents

Publication Publication Date Title
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
MX381417B (es) Inhibidores de glucosidasa.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
ECSP17054980A (es) Inhibidores selectivos de bace1
AR095097A1 (es) Compuestos de fenoxietoxi
AR105967A1 (es) Sales de un inhibidor de pim quinasa
EA201500931A1 (ru) Производные пиридин-4-ила
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
MX387796B (es) Compuestos de aminocarbonilcarbamato.
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
AR124083A2 (es) Nuevo inhibidor de sglt1